Evidence-based medicine in the treatment of ... - Alfredo Garofalo

98. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K et al.
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with
Stage III and Stage IV Ovarian Cancer. NEJM 1996; 334(1):1-6.
99. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al. Phase
III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients
With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
100. Albers DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA et al.
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus
intravenous cyclophosphamide for stage III ovarian cancer. NEJM 1996; 335:1950-1955.
101. Markman M, Bundy B, Albers DS, Fowler JM, Clark-Pearson DL, Carson LF et al.
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately highdose
carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume
stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group,
southwesters oncology group, and eastern cooperative oncology group. J Clin Oncology
2001; 19:1001-1007.
102. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez
RD,Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus
cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a
gynecologic oncology group study. J Clin Oncol. 2000 Jan;18(1):106-15.
103. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian
carcinoma. National Cancer Institute monograph 1975; 42:101-104.
104. Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz FJ. Survival Effect of
Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era:
A Meta- Analysis. Journal of Clinical Oncology 2002; 20(5):1248-1259.
105. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA et al.
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal
chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic
Oncology Group Study. Gyn Onc 2006; 100(1):27-32.
106. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR et al. A
pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin
as primary treatment of patients with small-volume residual ovarian cancer. Cancer
Chemother Pharmacol 1999; 43(2):106-114.
107. de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V et al.
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for
ovarian cancer. Anticancer Drugs 2003; 14(2):103-110.
108. Piso P, Dahlke MH, Loss M, Schlitt HJ.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal
carcinomatosis from ovarian cancer.
World J Surg Oncol. 2004 Jun 28;2:21.
109. Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo
M, Aranda E, Muntané J, Pera C. Radical surgery-peritonectomy and intraoperative
intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or
primary ovarian cancer.J Surg Oncol. 2006 Sep 15;94(4):316-24.